Metformina + Vildagliptina Ratiopharm (Metformin Hydrochloride, Vildagliptin)

Metformina + Vildagliptina Ratiopharm is used in the treatment of disorders related to impaired glucose regulation, primarily type 2 diabetes mellitus.

• Type 2 diabetes mellitus: improves overall glycaemic control when used alone or with other antidiabetic agents.
• Metabolic syndrome with hyperglycaemia: helps achieve target fasting and post‑prandial glucose levels.
• Combination therapy with other antidiabetics: provides additive glucose‑lowering effect for patients inadequately controlled on monotherapy.

• Metformin reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while Vildagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), leading to increased endogenous incretin levels that promote glucose‑dependent insulin secretion and suppress glucagon release, together producing a synergistic reduction in blood glucose.

Metformina + Vildagliptina Ratiopharm may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhoea: frequent loose stools, usually transient.
• Abdominal discomfort: cramping or pain.
• Headache: mild to moderate intensity.
• Dizziness: occasional light‑headedness.
• Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects

• Lactic acidosis: rare but life‑threatening metabolic disturbance.
• Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.
• Pancreatitis: acute inflammation of the pancreas.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Renal impairment: worsening kidney function, particularly with metformin.

Before initiating therapy, clinicians should consider several safety aspects.

• Renal function monitoring: assess eGFR before starting and periodically thereafter.
• Hepatic function assessment: evaluate liver enzymes prior to treatment.
• Risk of lactic acidosis: avoid in patients with severe renal or hepatic impairment.
• Elderly patients: start at lower dose and monitor for accumulation.
• Alcohol consumption: limit intake to reduce lactic acidosis risk.
• Store at room temperature: keep in the original container, protect from moisture and heat.

Metformina + Vildagliptina Ratiopharm can interact with other medicines; some require avoidance while others need careful monitoring.

Major Interactions (Avoid)

• Iodinated contrast media with metformin: may precipitate lactic acidosis in renal impairment.
• Cimetidine with metformin: increases metformin plasma concentrations.
• Strong CYP2C9 inhibitors with vildagliptin: raise vildagliptin exposure.

Moderate Interactions (Monitor Closely)

• Diuretics (e.g., furosemide) with metformin: can affect renal clearance.
• Insulin secretagogues (e.g., sulfonylureas) with vildagliptin: heighten hypoglycaemia risk.